Lung cancer proved the second-most discussed cancer type during ASCO 2025, totalling 2,995 mentions by more than 530 HCPs. As ...

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $16.00. The company’ ...

Active oncology biotech and pharma companies in the markets this week include Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), BioNTech SE (NASDAQ: BNTX), Arvinas, Inc.

Palm Beach, FL – June 11, 2025 – The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates ...

By Colin Kellaher Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Investing.com -- Shares of Arvinas Inc (NASDAQ: ARVN) climbed 1.6% while Pfizer Inc (NYSE: PFE) edged up 0.5% following the announcement of a New Drug Application (NDA) submission to the U.S. Food ...

Vepdegestrant Cuts Progression Risk by 43% in ESR1-Mutant Breast Cancer: In the Phase III VERITAC-2 trial, Arvinas and Pfizer’s vepdegestrant significantly reduced the risk of disease progression or ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's antibody-drug conjugate, Adcetrix, in combination with a chemotherapy regimen in ...

NEW HAVEN, Conn. and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial ...